Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis
Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 1055-1067.e6
DOI: 10.1016/j.cgh.2025.02.010 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Pinelopi Arvaniti und 59 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), …. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Hepatic Encephalopathy, Liver Cirrhosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Deutsche Forschungsgemeinschaft, European Commission.
Abstract (Originalsprache)
BACKGROUND & AIMS: Management of patients with autoimmune hepatitis (AIH)-related decompensated cirrhosis is challenging because of the risk of treatment-related complications and lack of clinical recommendations. We investigated the predictive factors for treatment benefit in AIH-related decompensated cirrhosis at diagnosis and developed an algorithm to guide treatment decisions in clinical practice. METHODS: This retrospective, international, multicenter study included 232 patients with histologically confirmed AIH-related decompensated cirrhosis at diagnosis. The sub-hazard ratio (SHR) of mortality was determined by competing risk analysis, considering liver transplantation (LT) as competing event. A decision tree analysis was used to develop a treatment algorithm. RESULTS: At diagnosis, 89% of patients had ascites, and 41% had overt hepatic encephalopathy (OHE). Treated patients (n = 214; 92%) had higher aminotransferases, bilirubin, and modified hepatic activity index. The SHR of mortality was lower in treated patients (0.438; 95% confidence interval [CI], 0.196-0.981; P = .045). Patients without OHE grade 3/4 and Model for End-Stage Liver Disease-Sodium (MELD-Na) ≤28 at diagnosis were more likely to benefit from treatment. In these patients, a decline in MELD-Na ≥11 after 4 weeks of treatment had a 100% negative predictive value for death/LT. Forty-nine percent of treated patients recompensated during follow-up. Twenty percent of patients had to discontinue treatment, 65% during the first 4 weeks, and only 4% due to infectious complications. OHE ≥grade 2 and MELD-Na at diagnosis predicted the need for treatment discontinuation. CONCLUSIONS: Immunosuppression is beneficial in patients with AIH-related decompensated cirrhosis and active disease. OHE and MELD-Na at diagnosis, along with a decline in MELD-Na at 4 weeks of treatment, are the most important determinants of outcome and can guide treatment decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Universitat de Barcelona, Barcelona, Spain; Department of Medicine and…
- Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Universitat de Barcelona, Barcelona, Spain; European Reference Network…
- Unidad de Autoinmunidad Hepática Sección de Hepatología y Trasplante Hepático, Hospital Italiano de Buenos Aires, Argentina.
- Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
- Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
- European Reference Network on Hepatological Diseases (ERN RARE-LIVER); Department of Gastroenterology and Hepatology, Liver Research Center, Ghent University Hospital, Ghent, Belgium.
Förderung
- Instituto de Salud Carlos III
- Deutsche Forschungsgemeinschaft
- European Commission
- Medizinischen Hochschule Hannover
- Hospital Clínic de Barcelona
Zitieren
APA
Arvaniti, P., Rodríguez-Tajes, S., Padilla, M., Olivas, I., Mauro, E., El Maimouni, C., Lytvyak, E., Verhelst, X., Engel, B., Taubert, R., Lorente-Pérez, S., Conde, I., Riveiro-Barciela, M., Ruiz-Cobo, J. C., Álvarez-Navascués, C., Salcedo, M., Gómez, J., Janik, M. K., Mateos, B., …, & European Reference Network on Hepatological Diseases (ENR RARE-LIVER) (2026). Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 24(4), 1055-1067.e6. https://doi.org/10.1016/j.cgh.2025.02.010
Vancouver
Arvaniti P, Rodríguez-Tajes S, Padilla M, Olivas I, Mauro E, El Maimouni C, et al. Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2026;24(4):1055-1067.e6. doi:10.1016/j.cgh.2025.02.010
BibTeX
@article{Arvaniti2026,
author = {Arvaniti, Pinelopi and Rodríguez-Tajes, Sergio and Padilla, Marlene and Olivas, Ignasi and Mauro, Ezequiel and El Maimouni, Cautar and Lytvyak, Ellina and Verhelst, Xavier and Engel, Bastian and Taubert, Richard and Lorente-Pérez, Sara and Conde, Isabel and Riveiro-Barciela, Mar and Ruiz-Cobo, Juan-Carlos and Álvarez-Navascués, Carmen and Salcedo, Magdalena and Gómez, Judith and Janik, Maciej K and Mateos, Beatriz and Efe, Cumali and Granito, Alessandro and Dajti, Elton and Azzaroli, Francesco and Horta, Diana and Vila, Carmen and Castello, Inmaculada and Pérez-Medrano, Indhira and Arencibia, Ana and Gerussi, Alessio and Bruns, Tony and Colaprieto, Francesca and Lleo, Ana and Van den Ende, Natalie and Verbeek, Jef and Díaz-González, Álvaro and Morillas, Rosa Ma and Torner-Simó, Maria and Bernal, Vanesa and Fernández, Eva-Maria and Gevers, Tom J G and Terziroli Beretta-Piccoli, Benedetta and Gómez, Elena and Cuenca, Paqui and de Boer, Ynte S and Kerkar, Nanda and Assis, David N and Liberal, Rodrigo and Drenth, Joost P H and Tana, Michele M and Sebode, Marcial and Schregel, Ida and Schramm, Christoph and Lohse, Ansgar W and Montano-Loza, Aldo J and Zachou, Kalliopi and Villamil, Alejandra and Dalekos, George N and Londoño, María-Carlota and International Autoimmune Hepatitis Group (IAIHG), International Autoimmune Hepatitis Group (IAIHG) and European Reference Network on Hepatological Diseases (ENR RARE-LIVER), European Reference Network on Hepatological Diseases (ENR RARE-LIVER)},
title = {Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {4},
pages = {1055--1067.e6},
doi = {10.1016/j.cgh.2025.02.010}
}
EUVIMED